Therapeutic Proteins International, LLC – Trademark Portfolio
Entity Type: 16
Therapeutic Proteins International, LLC holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 6 Nice Classification classes. The owner is based in Chicago, IL.
Suite 300
3440 S. Dearborn Street
Chicago, IL 60616
Showing of trademarks Trademarks
Trademark Classifications
Therapeutic Proteins International, LLC's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Therapeutic Proteins International, LLC have?
Therapeutic Proteins International, LLC has 26 U.S. trademarks filed with the USPTO.
What trademark classes does Therapeutic Proteins International, LLC file in?
Therapeutic Proteins International, LLC files trademarks across 6 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 36 (Insurance & Financial), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What is Therapeutic Proteins International, LLC's trademark registration success rate?
Therapeutic Proteins International, LLC has a 0% trademark registration rate, with 0 out of 26 resolved applications resulting in successful registration. Currently, 0 applications are pending review.